

9. Mai 2012

Press release from the company MPH Mittelständische Pharma Holding AG:

Aspects regarding the takeover of the majority of the capital in the company Windsor AG through the company MPH Mittelständische Pharma Holding AG
The company MPH Mittelständische Pharma Holding AG is a stock exchange listed company that strategically focuses on growth segments in the pharmaceutical market.

The company MPH AG was founded in the year 2008 and listed at the stock exchange in the year 2009. It is listed in the Entry Standard of the Frankfurt stock exchange.

The subsidiary company HAEMATO PHARM AG is a supplier of patent free and patent protected active substances with main focus on the therapeutic areas oncology, HIV, rheumatism, neurology and cardiovascular diseases. The company was founded in the year 2005 and registers a strong growth. A further company of the MPH-Group, the company HAEMATO Vet GmbH, markets veterinary pharmaceutical and veterinary medical products, as well as animal feed supplements in the large and small animal markets. The company was founded in the year 2010.

On May 7, 2012, the company MPH Mittelständische Pharma Holding AG announced the acquisition of roughly 52% of the capital of the company Windsor AG, Berlin.

The company Windsor AG is a stock exchange listed holding company. The company was founded in the year 1993. The business activity of the operative subsidiaries extends over two core areas - real estate and pharmaceuticals.

Through the pharmaceutical activities of the company Windsor AG the MPH-Group acquires access to new strong growth markets outside of Europe. The business operations of the pharmaceutical activities in the area of generics show a high-growth potential for turnover and earnings. The company Windsor AG has bundled its pharmaceutical area in the subsidiary companies SIMGEN GmbH and Pharmigon GmbH. The main areas of activity are the trading with active substances and pharmaceutical product dossiers, the marketing of pharmaceutical products overseas outside of Europe, as well as contract and order manufacturing.

Contact:

MPH Mittelständische Pharma Holding AG
Patricia Blechinger
Hubertusallee 73
D-14193 Berlin

Tel.: +49 (0) 30 897 30 86 60
Fax: +49 (0) 30 897 30 86 70

E-Mail: ir@mph-ag.de
Web: www.mph-ag.de

9. Mai 2012

With the majority shareholding of the company MPH AG in the company Windsor AG it will come to a close cooperation between both company groups, from which both sides anticipate substantial synergy effects. The MPH-Group thereby acquires access to additional know-how and can develop further potentials for the pharmaceutical area.

The development of the international business with generics is thereby of special strategic interest.

The real estate area within the company Windsor AG shows interesting yields, which – similar to the pharmaceutical value creation – are earned in a „defensive“ sector that hardly manifests any dependency on the economic cycle.

For the company MPH AG, as well as also for other shareholders the acquisition of Windsor shares means the acquisition of an attractively valued investment. For 5 million Windsor shares the company MPH AG issued 3.1 million MPH shares.

The company Windsor AG currently – after successful placements in the first quarter – holds financial assets of approximately 11% in the company MPH AG. After the majority takeover through the company MPH AG a further sale of the investment package is being considered. The financial means that will then become available could be invested in the development of the overseas outside of Europe pharmaceutical business of the Windsor-Group.

Public Relations

MPH Mittelständische Pharma Holding AG

Contact:

MPH Mittelständische Pharma Holding AG
Patricia Blechinger
Hubertusallee 73
D-14193 Berlin

Tel.: +49 (0) 30 897 30 86 60
Fax: +49 (0) 30 897 30 86 70

E-Mail: ir@mph-ag.de
Web: www.mph-ag.de